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Co-crystallization alters the molecular interactions and composition of pharmaceutical 
materials, and is considered better alternatives to optimize drug properties. Co-crystals 
consists of API and a stoichiometric amount of a pharmaceutically acceptable co-crystal 
former. Pharmaceutical co-crystals are nonionic supramolecular complexes and can be used to 
address physical property issues such as solubility, stability and bioavailability in 
pharmaceutical development without changing the chemical composition of the API. Co-
crystals can be constructed through several types of interaction, including hydrogen bonding, 
pi-stacking, and van der Waals forces. Co-crystals High Throughput provides information on 
relationship between formation and chemical structure of the API and conformer. Factors 
affecting co-crystal stability are reported and a co-crystal is only expected to form if it is 
thermodynamically more stable than the crystals of its components. Phase transformations 
induced during processing/storage affects the mechanisms of conversion of crystalline drugs 
to co-crystals. Pharmaceutical co-crystals could play a major part in the future of API 
formulation and can be employed for chiral resolution.  
 
KEYWORDS: Co-crystallization. Heterosynthon. Hydrogen bonding. Pharmaceutical co-
crystal. Polymorph. 
INTRODUCTION 
Poor dissolution rate, solubility, chemical stability and moisture uptake influence 
therapeutic efficacy of many pharmaceuticals, and significantly lower the market value of a 
drug. Multi-component crystals e.g. solvates, hydrates, co-crystals, salts play important role in 
the design of new solids particularly in the pharmaceutical area.   
CO-CRYSTALS 
Co-crystals incorporate pharmaceutically acceptable guest molecules into a crystal lattice 
along with the API. Co-crystals have regained attention as attractive alternate solid forms for 
drug development (Figure 1). Physiochemical properties of pharmaceuticals can be improved 
by obtaining co-crystals using co-crystallization 1-3. Co-crystallization with pharmaceutically 
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acceptable (GRAS) compounds does not affect pharmacological activity of API but can 
improve physical properties, such as solubility, hygroscopicity, compaction behavior 4-6. 












New opportunities for producing a larger diversity of solid forms of drug substances 
exhibiting the proper balance of important properties for development into a viable and 
effective drug product may be met by co-crystals 7. Furthermore, exploring the co-
crystallization potential around an API increases the intellectual property protection over a 
particular drug product; thus, reducing the risk of costly litigation and market erosion 1,8.  
Co-crystallization is a result of competing molecular associations between similar 
molecules, or homomers, and different molecules or heteromers 9. Hydrogen bonds are the 
basis of molecular recognition phenomena in pharmaceutical systems and are responsible for 
the generation of families of molecular networks with the same molecular components (single 
component crystals and their polymorphs) or with different molecular components (multiple 
component crystals or co-crystals) in the crystalline state 9.  
The components in a co-crystal exist in a definite stoichiometric ratio, and assemble via 
non-covalent interactions such as hydrogen bonds, ionic bonds, π-π or van der Waals 
interactions rather than by ion pairing 10. Generally, co-crystals in their pure states are solids 
at room temperature and by convention, these normally excludes salts. Co-crystals can have 
different properties than the crystals of individual components. Further, co-crystals  have  
different  crystal  structures  than  the  pure  components, contain different  intermolecular 
packing patterns, and as  such  they often exhibit widely different  physical  properties  than  
the  pure  components. Co-crystals are an alternative to salts when these do not have the 
appropriate solid state properties or cannot be formed due to the absence of ionization sites in 
the API 11,12.  
Co=crystals with the same active pharmaceutical ingredient will have strikingly different 
pharmaceutical properties (melting point, solubility, dissolution, bioavailability, moisture 
uptake, chemical stability, etc.), depending on the nature of the second component. Some of 
the co-crystals formed had higher and some lower melting points as compared to their pure 
components, for example, succinic acid (M. P. 135.3), urea (M. P. 188.9), co-crystal of 
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succinic acid-urea (M. P. 149.9) 13. Various type of studies on co-crystals involve i) selection 
of co-crystal formers for a specific API, ii) co-crystal screening of pharmaceutical active 
ingredients with selected co-crystal formers, iii) development of reliable procedures to 
prepare pharmaceutical co-crystals and nanoco-crystals, iv) characterization of 
pharmaceutical co-crystals, v) scale up of pharmaceutical co-crystals, and vi) co-crystal 
polymorphism.  
PHARMACEUTICAL CO-CRYSTALS  
The physical and chemical property improvements through pharmaceutical co-crystals 
draw closer the fields of crystal engineering and pharmaceutical sciences 14,15. A 
pharmaceutical co-crystal is a single crystalline solid that incorporates two neutral molecules, 
one being an API and the other a co-crystal former 16. Co-crystal former may be an excipient 
or another drug 6. Pharmaceutical co-crystal technology is used to identify and develop new 
proprietary forms of widely prescribed drugs and offer a chance to increase the number of 
forms of an API. Scientists showed that modifying the physical properties of a pharmaceutical 
compound through pharmaceutical co-crystal formation improved the performance of a drug 
known to have poor solubility 17. Pharmaceutical co-crystallization is a reliable method to 
modify physical and technical properties of drugs such as solubility, dissolution rate, stability 
hygroscopisity, and compressibility without alternating their pharmacological behavior 14,18. 
The expanding scope of crystal form selection, emergence of crystal engineering in 
pharmaceutical science and pharmaceutical co-crystals were reviewed 19. Some common 
aspects of co-crystal formation, screening strategies and outline methodologies for co-crystal 
functionality were reported 11. The use of co-crystals in drug design and delivery and as 
functional materials with potential applications as pharmaceuticals has recently attracted 
considerable interest 3,16,19-21. Pharmaceutical co-crystals have been described for many drugs 
such as acetoaminophen, aspirin, ibuprofen, flurbiprofen etc 6,16,22-24. Co-crystals of 
antitubercular drugs with dicarboxylic acids were reported using carboxylic acid-pyridine 
synthon as a reliable tool 25.  
CO-CRYSTAL VERSUS SOLVATES 
The main difference between solvates and co-crystals is the physical state of the isolated 
pure components: if one component is a liquid at room temperature, the crystals are 
designated as solvates; if both components are solids at room temperature, the crystals are 
designated as co-crystals. 
SALT VERSUS CO-CRYSTAL FORMATION 
Co-crystal and salts may sometimes be confused. The understanding of the fundamental 
difference between a salt formation and a co-crystal is very important to both pre-formulation 
activities and chemical/pharmaceutical development aspects. Indeed, salts and co-crystals can 
be considered as opposite ends of multi-component structures 7,26,27. Salt are often chosen 
instead of the free acid or base as these can improve crystallinity, solubility and stability of a 
pharmaceutical compound.  Co-crystals are an alternative to salts when these do not have the 
appropriate solid state properties or cannot be formed due to the absence of ionizable sites in 
the API. 
Ars Pharm, Vol. 50 nº2; 99-117. 
Sekhon BS. Pharmaceutical co-crystals - a review  102 
Salt formation is an acid–base reaction between the API and an acidic or basic substance. 
The widespread use of salt formation is evidenced by the large number of marketed 
crystalline salts of APIs 28,29. Salt formation is a three component system having an acid (A), a 
base (B) and one or more solvents. A salt is formed by transfer of a proton (H+) from an acid 
(A) to base (B).  
A-H + B → (A-) (B+- H) 
Proton transfer is thought to mainly depend on the pKa values of the components. The 
general rules for the packing of hydrogen bonded molecules in crystals were developed by 
Etter 30-32. When there is no such transfer and the components are instead present in the 
crystal as neutral entities, the product is generally defined as a co-crystal. In other words, a 
co-crystal is an A-B composite in which no proton transfer occurred.  
The formation of a salt or co-crystal can be predicted from pKa value of acid (A) and a 
base (B). Salt formation generally requires a difference of about 2.7 pKa units between the 
conjugate base and the conjugate acid (A) i.e. [ pKa (base) - pKa (acid ) ≥ 2.7]. For example, 
succinic acid having pKa 4.2 form co-crystal with urea base (pKa 0.1) while succinic acid 
form salt with L-lysine base having pKa 9.5 . Generally base pKa values are not sufficiently 
high to allow proton transfer when co-crystal is formed 33. Co-crystal of succinic acid-urea 
has two hydrogen bonds i.e. the oxygen atom in urea molecule is bonded to hydrogen atom in 
succinic acid molecule while oxygen atom from succinic acid molecule is bonded to hydrogen 
atom in urea molecule (Figure 2).  
















The two-component crystals formed from pyridine or 4-dimethylaminopyridine with 
maleic, fumaric, phthalic, isophthalic, or terephthalic acids indicated that the two-component 
solid forms involving pyridine included both salts and co-crystals, while 4-
dimethylaminopyridine crystallized exclusively as a salt, in agreement with the differences in 
the pKa values 34. Relocating the acid protons in the salts to produce co-crystals and vice 
versa, computational modeling experiments showed that the crystal structure can be better 
modeled when the crystallographic designation of salt or co-crystal is used 34. 
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SCREENING OF CO-CRYSTALS 
Co-crystals can be prepared from two  molecules  of  any  shape  or  size  having  
complementary  hydrogen  bond functionalities. The ability of an API to form a co-crystal is 
dependent on a range of variables, including the types of co-former, the API co-former ratio, 
the solvents, the temperature, the pressure, the crystallization technique, etc. Experimental 
screening for co-crystal formers is not trivial. Synthesis/processing of co-crystals can be 
accomplished via a number of methods, including slow solvent evaporation crystallization 
from solution, solvent-reduced (e.g. slurrying, solvent-drop grinding) and solvent-free [e.g. 
grinding, melt [(hot stage microscopy)], high throughput crystallization and co-sublimation 
techniques 14, 26, 35-44. Typically co-crystals are prepared by slow solvent evaporation that is 
only viable if compatible solubility in a given solvent exists between the components 
comprising the potential co-crystal. The potential benefits, disadvantages and methods of 
preparation of co-crystals were reported 45. Solvent drop grinding has been reported to be a 
cost-effective, green, and reliable method for discovery of new co-crystals as well as for 
preparation of existing co-crystals 46. A slurry crystallization technique was used in co-crystal 
screening of two nonionizable pharmaceutical host compounds, stanolone and mestanolone, 
with 11 pharmaceutically acceptable guest acids and results demonstrated the importance not 
only of hydrogen bonding but also of geometric fit in co-crystal formation 38. 
Scientists reported the synthesis (via solvent-drop grinding, solution evaporation, or 
crystallization from solution), crystal structures, and basic physicochemical properties of six 
co-crystals of piracetam with l-tartaric acid, citric acid, racemic mandelic acid, l-mandelic 
acid, as well as a piracetam−citric acid ethanol solvate. Compared to piracetam the 
piracetam−l-tartaric acid co-crystal showed improved hygroscopic properties 47. Scientists 
reported that liquid-assisted grinding appears to be a more efficient method of screening for 
co-crystal hydrates 48. The combinations and variations of the above techniques may be used 
to cause co-crystal formation 49 [33n]. However, co-crystal screening is difficult to automate 
and labor intensive. The importance of understanding ‘‘supramolecular synthons’’ in 
synthesizing co-crystals containing pharmaceutical agents have been reported 17, 44. Recently, 
it has been reported that molecules which crystallize with Z′ > 1 showed a markedly stronger 
tendency to form co-crystals than compounds that crystallize in the pure form with Z′ = 1 50. 
Co-crystal formation between caffeine and adipic acid has been reported utilizing the newly 
developed co-crystal screening method 51. The carboxylic acid–primary amide supramolecular 
heterosynthon has been exploited for the generation of pharmaceutical co-crystals containing 
two active pharmaceutical ingredients that are polymorphic in their pure forms 22. The factors 
and conditions governing the formation and stability of co-crystals with different 
stoichiometry were reported with carbamazepine−4-aminobenzoic acid (CBZ−4ABA) co-
crystals as the model system. A 1:1 CBZ−4ABA co-crystal was discovered by the reaction 
crystallization method and co-crystal characterized by carboxylic acid···acid and 
amide···amide homosynthons. The stability of 2:1 and 1:1 co-crystals depend on ligand 
solution concentration and the co-crystal richer in ligand component was more stable at 
higher ligand solution concentrations 52.  
A review of several aspects of co-crystallization involving sulfadimidine with a focus on 
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other drug molecules as co-crystallization partners has been reported 53. Co-crystal forming 
abilities of the two anti-HIV drugs (lamivudine and zidovudine) were studied to investigate 
the general applicability of the retrosynthetic approach in the design of new co-crystals. It was 
reported that both screening strategies and retrosynthetic methods were appropriate for the 
discovery of new active pharmaceutical ingredients co-crystals 54. Trimer co-crystals of cis-
itraconazole-succinic acid have been prepared and characterized by single-crystal X-ray. The 
extended succinic acid molecule filled the pocket, bridging the triazole groups through 
hydrogen-bonding interactions rather than interacting with the more basic piperazine 
nitrogens. Further, the results suggested that co-crystals of drug molecules have the possibility 
of achieving the higher oral bioavailability normally observed for amorphous forms of water-
insoluble drugs. In addition, the long-term chemical and physical stability provided by crystal 
forms was maintained 17. The co-crystals (4,4‘-biphenol)3·(2-aminopyridine)2 , (4,4‘-
biphenol)·(caprolactam)2 , and (resorcinol)·(caprolactam)2  were reported to self-assemble in 
the form of supramolecular heterocatemers and provided insight into a possibly general 
approach for the crystal engineering of co-crystals 55. The co-crystal of the model 
pharmaceutical compound caffeine with oxalic acid exhibited complete stability to humidity 
over a period of several weeks 56. The results on the formation of stoichiometric variations, 
i.e. co-crystals composed of identical molecular building blocks in different stoichiometric 
ratios using co-crystals composed of nicotinamide (na) and suberic acid (sub) as co-crystal 
former suggested that the co-crystal formation occurred in a stepwise manner, wherein the co-
crystal (na)·(sub) appeared as an intermediate in the synthesis of the (na)2·(sub) co-crystal 57.  
Co-crystal prediction has been reported to include the following steps: (1) determining 
whether a given set of two or more molecular components will undergo co-crystallization; (2) 
identifying the primary intermolecular interactions, e.g., hydrogen-bond motifs that will exist 
within a particular co-crystal structure; and (3) envisioning the overall packing arrangement in 
the resulting co-crystal structure 8. The comparison of the spectrum of a co-crystal to co-
added spectra of co-crystal formers represents a quick and easy judgment of co-crystal 
formation (or otherwise). Researchers suggested that compared to infrared, Raman 
Spectroscopy would be the technique of choice for rapidly checking co-crystal formation 58-64. 
Scientists demonstrated the potential of supercritical fluid techniques which include [the Co-
crystallization with Supercritical Solvent technique, the Supercritical Anti-Solvent technique), 
and the Atomization and Anti-Solvent technique] as screening methods for co-crystals using 
indomethacin-saccharin co-crystalline system as model system 65.  
Pure component solubilities determine the concentration regions to screen for new co-
crystals, rather than the stoichiometry of the co-crystal. Based on this, new co-crystals of 
carbamazepine with isonicotinamide, benzamide and 3-nitrobenzamide, and of cinnamic acid 
with 3-nitrobenzamide have been reported 66. Scientists described the use of neat and liquid-
assisted grinding for screening for hydrated forms of pharmaceutical co-crystals, and liquid-
assisted grinding was found less sensitive to the form of the reactant (i.e., hydrate or 
anhydrate) than neat grinding 67. Results on pharmaceutical co-crystals construction involving 
theophylline and caffeine as pharmaceutical ingredients and L-malic or L-tartaric acid as 
pharmaceutical co-crystal formers showed that co-crystal formation occurred under conditions 
in which all co-crystal components remain saturated 68. Scientists reported a pharmaceutical 
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co-crystal formed between an inorganic acid and an API, which enabled the development of a 
stable crystalline and bioavailable solid dosage form for pharmaceutical development where 
otherwise only unstable amorphous free form or salts could have been used 69. Novel 
pharmaceutical co-crystal e.g. norfloxacin saccharinate dihydrate and its co-crystal, 
norfloxacin saccharinate–saccharin dihydrate, were reported 70. A role for co-crystal formers 
as hydrogen bond additives that favor and stabilize specific motifs for the crystallization of 
new polymorphs has been reported for phloroglucinol and phenazine co-crystals of 1:1.5, 
1:1.75, and 1:2 stoichiometry 71.  
A co-crystal is only expected to form if it is thermodynamically more stable than the 
crystals of its components. Computational attempts have been made to predict co-crystal 
formation 72,73.  
Scientists have observed that liquid-assisted grinding of two enantiomorphic co-crystals 
resulted in to either formation of a centrosymmetric three-component co-crystal, consisting of 
the left- and right-handed co-crystal former molecules and the model API or the model API 
along with the racemic form of the co-crystal former 74. Grinding together of theophylline and 
D- or L-tartaric acid produced co-crystals that contained theophylline and the co-crystal 
former in a 2:1 stoichiometric ratio, wherein caffeine and D- or L-tartaric acid produced co-
crystals that contained the two components in a 1:1 ratio 74. Carboxylic acid co-crystals of 
fluoxetine hydrochloride provided the opportunity to modify physical properties while 
retaining the salt form in the co-crystal structure 75.  
MECHANISM FOR CO-CRYSTAL SYNTHESIS 
Amorphous phases generated by pharmaceutical processes lead to co-crystal formation 
during cogrinding and storage.76. The mechanisms underlying moisture uptake generated co-
crystals of carbamazepine-nicotinamide, carbamazepine-saccharin, and caffeine or 
theophylline with dicarboxylic acid ligands (oxalic acid, maleic acid, glutaric acid, and 
malonic acid) when solid mixtures with co-crystal reactants were exposed to deliquescent 
conditions involve (i) moisture uptake, (ii) co-crystal aqueous solubility, (iii) solubility and 
dissolution of co-crystal reactants, and (iv) transition concentration 7,77. For carbamazepine: 
nicotinamide co-crystal synthesis, nucleation and growth of co-crystals were directed by the 
effect of the co-crystal components on reducing the solubility of the molecular complex to be 
crystallized 78 .  
A molecular-level mechanism for two cases of mechanochemical co-crystallization via 
halogen bonds was reported and was based on the observation and structural characterization 
of intermediates that appeared in early stages of the reaction. The mechanism arises from the 
competition of strong and weak intermolecular halogen bonds of the N...I and S...I type and 
involves the initial formation of finite molecular assemblies, held together via N...I bonds that 
subsequently polymerize into infinite chains by cross-linking through S...I bonds 79. Co-
crystallizations of exemestane and megestrol acetate improved initial dissolution rates 
compared to the respective original crystals. The mechanism of dissolution enhancement 
varied. With exemestane/maleic acid co-crystal, fine particle formation resulted in 
enhancement, whereas with megestrol acetate /saccharin co-crystal, enhancement was due to 
the maintenance of the co-crystal form and rapid dissolution before transformation to the 
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original crystal 80.  
The mechanisms of conversion of crystalline drugs to co-crystals and factors affecting co-
crystal stability were reported. Coformer solution concentration controlled the formation and 
stability of different stoichiometry co-crystals. Studies with 1:1 and 2:1 carbamazepine-4-
aminobenzoic acid co-crystals indicated that the co-crystal richer in coformer was found more 
stable at higher conformer concentration.  Co-crystallization also occurred in solid mixtures 
of co-crystal reactants. Co-crystals of carbamazepine-nicotinamide, carbamazepine-saccharin, 
and caffeine or theophylline with various carboxylic acid coformers were formed due to 
moisture sorption and deliquescence in reactant mixtures. In the solid-state, cogrinding 
carbamazepine with saccharin or nicotinamide formed co-crystals 6,77,81.  
 
CHARACTERIZATION OF CO-CRYSTALS 
Characterization of co-crystals involves both structure (infrared spectroscopy, single 
crystal x-ray crystallography and powder x-ray diffraction) 82-84 and physical properties (e.g. 
melting point apparatus, differential scanning calorimetry, thermogravimetric analysis) 84, 85. 
The analytical potential of NIR spectroscopy for co-crystal screening using Raman 
spectroscopy as a comparative method has been reported 86. A compound-sparing, automated 
and green  differential scanning calorimetric method was developed for rapid co-crystal 
screening which demonstrated the formation of carbamazepine - nicotinamide co-crystals 87. 
Co-crystals of a phosphodiesterase-IV inhibitor with L-tartaric acid were characterized 88. Co-
crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as 
inhibitors of Bcl-2 family proteins and use of co-crystals of (−)-gossypol with a C1-8 
carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to 
the induction of apoptotic cell death were  characterized ((e.g. (-)-Gossypol- acetic acid co-
crystals )89. Single crystals of the 1:1 co-crystal of piracetam and gentisic acid    obtained via 
slow evaporation from acetonitrile. Co-crystal or prepared via grinding or slurrying in water 
was characterized by IR, melting point, DSC, PXRD and single crystal X-ray diffraction 20.  
Plots of pH versus solubility were employed to compare the solubility of molecular salts 
and co-crystals 90. Mathematical model was developed that describes the solubility of co-
crystals by taking into consideration the equilibria between co-crystal, co-crystal components, 
and solution complexes and was applied to the phase diagrams of 
carbamazepine/nicotinamide co-crystal in organic solvents. The dependence of co-crystal 
solubility on solubility product and complexation constants provided a powerful approach to 
design co-crystal screening methods and to formulate solutions with co-crystal components 
where crystallization does not occurred 91. A method was developed to estimate the co-crystal 
solubility in pure solvent and co-crystal solubility was found to be directly proportional to the 
solubility of constituent reactants for carbamazepine, caffeine, and theophylline co-crystals 92. 
The phase transformation of API to co-crystal has been shown to depend on solution and co-
crystal chemistry where non-stoichiometric concentrations of co-crystal reactants lead to 
thermodynamically favorable conditions for co-crystallization.  A reaction crystallization 
method for co-crystal screening and synthesis based on the above principles has been reported 
as applied to various systems including the generation of co-crystals by moisture sorption 
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78,91.  
A new approach to model co-crystal phase diagrams was recently reported and its 
application to an active pharmaceutical ingredient and glutaric acid co-crystal demonstrated 
good agreement between calculated and experimental data 93. The indomethacin- saccharin 
co-crystal was formed with carboxylic acid and imide dimer synthons interconnected by weak 
N-H...O hydrogen bonds showed considerably faster dissolution rate than that of the stable 
indomethacin gamma-form 84. Researchers recently reported a stable API-glutaric acid co-
crystal having 18-times-greater dissolution rate in water and three-times-higher blood plasma 
concentrations 61. Co-crystals of the API piroxicam were characterized for many carboxylic 
acids 60. The scientists provided the foundation to experimentally assess the thermodynamic 
stability of a co-crystal with respect to its component forms using data for the carbamazepine–
nicotinamide system 94. Co-crystal formation should generally be predictable by comparing 
the relative stability of the most stable co-crystal and its pure components found on the 
computed crystal energy landscapes 72. The thermodynamically favored structure prediction 
of the co-crystals of p-aminobenzoic acid with 2,2'-bipyridine, based only on the atomic 
connectivity of the component molecules and assumed stiochiometry was reported 95.  
The most stable solid form of tiotropium fumarate i.e. a new salt-co-crystal of tiotropium 
fumarate with fumaric acid structure consisted of matched cations and anions (a salt) together 
with a nonionized free acid moiety as the co-former (co-crystal), and is unique amongst the 
large number of tiotropium salts that have been prepared and characterized. The stoichiometry 
cation/anion/co-former of 2:1:1 corresponded to a simple polymorph of the 1:1 salt, and its 
identity as a co-crystal has been established by single-crystal X-ray diffraction with some 
corroborating evidence from the Raman and infrared spectra. A detailed investigation of the 
bonding and geometry of the three crystalline forms of the fumarate indicated that the 
hydrogen bonding motifs are very similar, and that conformational differences arising from 
the packing of the two thiophene rings into the crystal structure is probably important in 
determining their relative stabilities. A comparison with the structures of other tiotropium 
salts indicated a correlation of the dihedral angle between the two tiotropium thiophene rings 
with the stability of the crystal forms 96. Helical-type of chiral co-crystal of tryptamine and 
hydrocinnamic acid prepared by crystallization in the presence of different chiral crystals 
have similar crystal structures, despite spontaneous crystallization itself giving only achiral 
crystal 97. Curcumin, the main component of the spice turmeric, has been successfully used as 
a therapy to treat human multiple myeloma 98 [76a].and also has shown to possess anti-
inflammatory and anti-cancer activities 99. However, curcumin has extremely poor water 
solubility and bioavailability. A series of pharmaceutically acceptable co-crystal formers are 
under investigation to screen for co-crystal formation of curcumin 99.  
NANOCRYSTAL AND NANOPHARMACEUTICAL CO-CRYSTALS 
A nanocrystal refers to any nanomaterial with at least one dimension ≤ 100nm and it 
should be single crystalline 100,101. The production of drug nanocrystals by bottom up 
techniques (with main focus on particle diminution by high pressure homogenization) for 
many new chemical entities of very low solubility has been reported. The transfer of the 
liquid nanosuspensions to patient convenient oral dosage forms such as tablets and capsules 
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have also been reported 102. Under microwave irradiation, nonlinear optical nanococrystals of 
aminonitropyridines with benzenesulfonic acids were reported 103. Single-component 
crystalline nanorods, composed of 9-methylanthracene (9-MA) and exposed to a suspension 
of 1,2,4,5-tetracyanobenzene (TCNB) in water formed a 1:1 charge-transfer complex within 
the rods, which are transformed from crystalline 9-MA into co-crystalline 9-MA/TCNB. The 
co-crystal nanorods were characterized by electron microscopy, X-ray diffraction, and optical 
spectroscopy. These studies demonstrated the importance of organic nanostructures for 
supporting structure-preserving chemical transformations that were not possible in larger 
crystals 104. Nanostructured co-crystals exhibiting single-crystal-to-single-crystal chemical 
reactivity were constructed by Sonochemistry 105.  
POLYMORPHISM OF CO-CRYSTALS  
Polymorphism in multi-component crystals is gaining interest in the recent times in the 
context of pharmaceutical co-crystals. Polymorphs have different stabilities and may 
spontaneously convert from a metastable form (unstable form) to the stable form at a 
particular temperature. In addition, they exhibit different melting points and solubilities which 
affect the dissolution rate of drug and thereby, its bioavailability in the body. Co-crystal 
polymorphs suggest additional options to modify properties, increase patent protection, and 
improve marketed formulations. Co-crystals of 4-hydroxybenzoic acid and 2,3,5,6-
tetramethyl-pyrazine (2 : 1) exhibited the first supramolecular synthon polymorphism in a co-
crystal; metastable anti-hierarchic polymorph I was converted to stable hierarchic form II 106. 
Preparation of polymorphic co-crystals I and II (temozolomide: 4,4 -bipyridine-N,N -dioxide 
(1:0.5 and 2:1) were optimized by using solution crystallization and grinding methods. The 
metastable nature of co-crystal II was ascribed to unused hydrogen-bond donors/acceptors in 
the crystal structure 107.  
Two polymorphs of carbamazepine-nicotinamide co-crystals and two polymorphs of 
carbamazepine-saccharin co-crystals were found to be polymorphic108. Co-crystal polymorphs 
of carbamazepine and isonicotinamide having 1:1 stoichiometry were reported which were 
formed through a solvent-mediated transformation process upon suspending a dry mixture of 
the pure crystalline components in ethanol 109. Two polymorphs of a co-crystal between 2-
ethoxybenzamide and saccharin sustained by a carboxamide–imide heterosynthon involving 
two N–H O hydrogen bonds were prepared and structurally characterized by single crystal 
X-ray diffraction. The only metastable Form II was formed in the grinding experiments, 
whereas both polymorphs were reported by solution crystallization. It is worthy to note that 
the number of polymorphs of a co-crystal was more than the number of polymorphs of its 
parent API. The importance of this multiple screening techniques for co-crystal polymorphs 
sheds light on the ability of the solid-state grinding to produce the metastable polymorph of a 
co-crystal 110. Co-crystals of piroxicam with carboxylic acids were prepared and various 
groups of co-crystals containing piroxicam and a guest carboxylic acid were differentiated by 
the piroxicam tautomer present in the co-crystal and the presence or absence of a strong 
hydrogen bond donor interacting with piroxicam's amide carbonyl group. Further, two 1:1 
piroxicam/4-hydroxybenzoic acid co-crystals were found to be polymorphs 60.   
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PHARMACEUTICAL CO-CRYSTALS AS INTELLECTUAL PROPERTY 
Compared to other classes of solid forms, co-crystals possessed particular scientific and 
regulatory advantages, and alongside these advantages were intellectual property issues which 
give co-crystals with unique opportunities and challenges. Researchers reported the 
importance regarding patents on pharmaceutical co-crystals to the pharmaceutical industry 8. 
The value of co-crystals to the pharmaceutical industry should become clearer, mainly with 
respect to several relevant legal and regulatory issues, as products containing co-crystal 
technology come out from pharmaceutical development pipelines onto the market.  
APPLICATIONS OF CO-CRYSTALS 
Compared to other solid-state modification techniques employed by pharmaceutical 
industry, co-crystal formation appears to be an advantageous alternative for drug discovery 
(e.g. new molecule synthesis, nutraceutical co-crystals), drug delivery (solubility, 
bioavailability) and chiral resolution 16, 18, 19,111. Experts are of the opinion that pharmaceutical 
intellectual property landscape may benefit through co-crystallization 8.  
CONCLUSIONS AND PERSPECTIVES 
Pharmaceutical co-crystals represent a advantageous class of crystal form in the context of 
pharmaceuticals. Co-crystals of drugs and drug candidates represent a new type of material 
for pharmaceutical development. Co-crystals are relatively new to pharmaceutical industry 
and pharmaceutical co-crystals have given a new direction to deal with problems of poorly 
soluble drugs. Co-crystals have the potential to be much more useful in pharmaceutical 
products than solvates or hydrates.  
The relevance of co-crystals in API formulation includes the ability to fine-tune physical 
properties, characterization of API, identify and develop new, proprietary forms of prescribed 
drugs and the opportunity to generate intellectual property.  
Further research is desirable in order to scale up co-crystal systems and implement 
manufacturing of final dosage forms on commercial scale. Screening for solid forms is 
important to guarantee that the optimum form is carried forward in development and to 
minimize the likelihood of unexpected form conversion. Co-crystals – High Throughput gives 
vital information on relationship between formation and chemical structure of the API and co-
former. Screening of API’s with library of co-crystal formers requires further investigations to 
include all possible coformers. Studies regarding polymorphism of co-crystals should be 
strengthrd in order to accelerate the development of new pharmaceuticals. Additional 
developments in screening methodology will further elevate the profile of co-crystals on the 
pharmaceutical and intellectual property landscapes. 
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